Riskpilot← Back to searchSign inGet full accessNORMEDI NORGE AS
ASActiveOrg 914423562Åshaugveien 68, 3170 SemWholesale of pharmaceutical and medical goods · NACE 4646Est. 20142 employees
Revenue 2025
NOK 34,2M
+20% vs 2024
EBITDA margin
8.9%
+143% vs 2024
Equity ratio
41.6%
Financial strength
Net profit 2025
NOK 2,1M
+162% vs 2024
| Revenue | NOK 34,2M | +20% |
| EBITDA | NOK 3M | +143% |
| Net profit | NOK 2,1M | +162% |
| Total assets | NOK 9,5M | +50% |
| Equity | NOK 3,9M | +109% |
| Employees | 2 | — |
Legal name
NORMEDI NORGE AS
Org number
914423562
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
7. november 2014
Share capital
NOK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Salg og markedsføring av medisintekniske produkter i norge.
Address
Åshaugveien 68, 3170 Sem
Phone
+4733320400
Email
support@normedi.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 12 987 | 17 145 | 14 607 | 28 496 | 34 157 |
| Staff expenses | −2 049 | −2 641 | −2 137 | −4 284 | −4 100 |
| EBITDA | 1 225 | 1 107 | 433 | 1 251 | 3 034 |
| Depreciation & amort. | −86 | −77 | −73 | −136 | −243 |
| EBIT | 1 138 | 1 030 | 360 | 1 115 | 2 791 |
| Net financials | −13 | −129 | −144 | −83 | −137 |
| Profit before tax | 1 126 | 900 | 216 | 1 033 | 2 654 |
| Tax | 253 | 201 | 55 | 249 | 599 |
| Net profit | 873 | 699 | 161 | 784 | 2 055 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 195 | 3 793 | 4 179 | 6 297 | 9 455 |
| Equity | 234 | 933 | 1 094 | 1 878 | 3 933 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 961 | 2 861 | 3 086 | 4 419 | 5 522 |
| Total debt | 2 961 | 2 861 | 3 086 | 4 419 | 5 522 |
EBITDA margin
8.9%
This company
15.8%
Market median
-44% vs market
20212025
Equity ratio
41.6%
This company
38.2%
Market median
+9% vs market
20212025
Return on equity
52.3%
This company
18.4%
Market median
+184% vs market
20212025
Net profit margin
6.0%
This company
8.1%
Market median
-26% vs market
20212025
Asset turnover
3.61×
This company
1.12×
Market median
+222% vs market
20212025
Debt / equity
1.40×
This company
0.62×
Market median
-126% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-09-30
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JS Chief Executive Officer | Chief Executive Officer | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Former (1) | ||
| Chairman | 2014 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Normedi Nordic As
NORMEDI NORGE AS Board members of NORMEDI NORGE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jesper Steffensen | Chief Executive Officer | 0 companies |
| Øystein Granne Norling | Chairman | 0 companies |
| Joao Paulo Falcao Malagueira | Board of Directors | 0 companies |
| Michelangelo Stefani | Chairman | 0 companies |